[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Celcuity Inc (CELC)

Celcuity Inc (CELC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,445,888
  • Shares Outstanding, K 48,766
  • Annual Sales, $ 0 K
  • Annual Income, $ -177,040 K
  • EBIT $ -187 M
  • EBITDA $ -183 M
  • 60-Month Beta 0.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 124.33

Options Overview Details

View History
  • Implied Volatility 75.95% (-2.46%)
  • Historical Volatility 73.15%
  • IV Percentile 54%
  • IV Rank 9.34%
  • IV High 317.42% on 07/25/25
  • IV Low 51.06% on 08/19/25
  • Expected Move (DTE 30) 19.21 (14.67%)
  • Put/Call Vol Ratio 0.51
  • Today's Volume 1,256
  • Volume Avg (30-Day) 3,016
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 32,948
  • Open Int (30-Day) 31,899
  • Expected Range 111.75 to 150.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.18
  • Number of Estimates 3
  • High Estimate $-1.08
  • Low Estimate $-1.35
  • Prior Year $-1.04
  • Growth Rate Est. (year over year) -13.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
106.58 +22.87%
on 04/24/26
151.02 -13.28%
on 05/04/26
+8.50 (+6.94%)
since 04/17/26
3-Month
100.01 +30.95%
on 03/24/26
151.02 -13.28%
on 05/04/26
+24.18 (+22.64%)
since 02/19/26
52-Week
10.26 +1,176.41%
on 05/27/25
151.02 -13.28%
on 05/04/26
+120.27 (+1,125.07%)
since 05/19/25

Most Recent Stories

More News
Celcuity Q1 Earnings Call Highlights

Celcuity (NASDAQ:CELC) reported a wider first-quarter loss as the biotechnology company increased spending tied to commercial launch preparations and continued development of gedatolisib, its investigational...

CELC : 130.96 (-0.92%)
Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update

  Phase 3 VIKTORIA-1 trial achieved primary endpoint with clinically meaningful improvement in progression-free survival in PIK3CA mutant cohort; detailed data for gedatolisib regimens will be presented...

CELC : 130.96 (-0.92%)
Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients

MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid...

CELC : 130.96 (-0.92%)
Celcuity Reports After Analysts Raised Targets But Before ASCO Presents the Data

Barchart Research What to Expect from CELC Earnings CELC Generated May 13, 2026 Current Price $124.47 EPS Estimate $$-1.07 Consensus Rating Strong Buy Average Move 4.10% Celcuity Reports After Analysts...

CELC : 130.96 (-0.92%)
Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call

MINNEAPOLIS, May 07, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will...

CELC : 130.96 (-0.92%)
Stocks Fall Amid Rising Middle East Tensions

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.41%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -1.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.21%. June E-mini...

MSTR : 164.63 (-1.20%)
SNDK : 1,383.29 (+3.77%)
GLXY : 27.55 (-1.15%)
COIN : 193.45 (+2.12%)
STX : 733.35 (-1.01%)
WDC : 455.80 (-0.63%)
UPS : 96.83 (+1.36%)
^BTCUSD : 76,759.02 (-0.26%)
SPY : 733.73 (-0.67%)
GME : 22.10 (+0.87%)
ADSK : 244.16 (+0.28%)
MU : 698.74 (+2.52%)
Stocks Mixed on Middle East Tensions and Solid Corporate Earnings

The S&P 500 Index ($SPX ) (SPY ) today is down -0.04%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.42%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.19%. June E-mini S&P futures (ESM26...

MSTR : 164.63 (-1.20%)
AMAT : 406.91 (-1.61%)
SNDK : 1,383.29 (+3.77%)
INTU : 399.71 (-0.86%)
CELC : 130.96 (-0.92%)
GLXY : 27.55 (-1.15%)
EXPD : 157.60 (+0.53%)
$IUXX : 28,818.84 (-0.61%)
COIN : 193.45 (+2.12%)
ZNM26 : 108-225s (-0.29%)
MSFT : 417.42 (-1.44%)
PRU : 101.16 (-1.77%)
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort

MINNEAPOLIS, May 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced positive topline...

CELC : 130.96 (-0.92%)
Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

The U.S. Food and Drug Administration (“FDA”) accepted Celcuity’s New Drug Application (“NDA”) and granted Priority Review with a Prescription Drug User Fee Act (“PDUFA”) goal date of July...

CELC : 130.96 (-0.92%)
Celcuity Faces Widening Losses as Analysts Await Critical Earnings Report

CELC : 130.96 (-0.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company's proprietary CELx diagnostic platform uses a patient's...

See More

Key Turning Points

3rd Resistance Point 143.31
2nd Resistance Point 139.55
1st Resistance Point 135.26
Last Price 130.96
1st Support Level 127.21
2nd Support Level 123.45
3rd Support Level 119.16

See More

52-Week High 151.02
Last Price 130.96
Fibonacci 61.8% 97.25
Fibonacci 50% 80.64
Fibonacci 38.2% 64.03
52-Week Low 10.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.